Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with advanced solid tumors.

Study Overview

• Status: Completed
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: aldoxorubicin

Detailed Description

An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin Administered as a 30 Minute Infusion Every 3 Weeks in Subjects with Advanced Solid Tumors.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90048
      • Samuel Oschin Comprehensive Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age ≥18 years, male or female.
2. Histologically or cytologically confirmed malignant solid tumor that has relapsed or is refractory to standard therapy.
3. Subjects who have received prior radiation therapy with stable central nervous system (CNS) metastasis with no progression of brain metastasis by CT/MRI scan in last 4 weeks.
4. Capable of providing informed consent and complying with trial procedures.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
6. Life expectancy >12 weeks.
7. Measurable or evaluable disease.
8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. [Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.].
9. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
10. Geographic accessibility to the site.

Exclusion Criteria:

1. Palliative surgery, chemotherapy, immunotherapy and/or radiation treatment less than 4 weeks prior to the Screening Visit.
2. Exposure to any investigational agent within 30 days of the Screening Visit.
3. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or 5 times the ULN in liver metastases, total bilirubin greater than 3 times the ULN, white blood cell (WBC) count <3500/mm3, absolute neutrophil (ANC) count < 2000/mm3, platelet concentration <100,000/mm3, hematocrit level <25% for females or <28% for males (transfusion is allowed during screening).
4. Clinically evident congestive heart failure (CHF) > class II of the New York Heart Association (NYHA) guidelines.
5. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
6. Recent history (within 6 months) or current signs of active coronary artery disease with or without angina pectoris.
7. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) <45% of predicted.
8. Known history of HIV infection.
9. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or antifungals.
10. Major surgery within 4 weeks prior to treatment.
11. Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
12. Any condition that is unstable and could jeopardize the subject's participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Aldoxorubicin; Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.	Drug: aldoxorubicin; Other Names: INNO-206

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics	Blood samples will be obtained for pharmacokinetics. Standard pharmacokinetic parameters, including t1/2, Cmax, AUC, Vd and CL, will be determined.	up to 3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety	All subjects who receive any amount of aldoxorubicin will be included in the safety analyses, which will include the following: The incidence, severity, duration, causality, seriousness, and type of AEs and changes in the subject's physical examination, vital signs, and clinical laboratory results.; Deaths and other SAEs will be tabulated.	up to 6 months

Collaborators and Investigators

• Sponsor: ImmunityBio, Inc.
• Investigators: Study Director: Dan Levitt, MD, CytRx Coorporation

Study record dates

Study Major Dates

• Study Start: October 1, 2012
• Primary Completion (ACTUAL): December 1, 2014
• Study Completion (ACTUAL): December 1, 2014

Study Registration Dates

• First Submitted: October 11, 2012
• First Submitted That Met QC Criteria: October 12, 2012
• First Posted (ESTIMATE): October 15, 2012

Study Record Updates

• Last Update Posted (ACTUAL): February 10, 2022
• Last Update Submitted That Met QC Criteria: January 27, 2022
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Keywords: phase 1; pharmacokinetic; solid tumor; INNO-206; aldoxorubicin
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: ALDOXORUBICIN-P1-PK-01